Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING LLC
FOCUS DIAGNOSTICS, INC.

Blood Test Helps Identify Depressed Patients

By Labmedica International staff writers
Posted on 14 Feb 2012
A blood test helps diagnose major depressive disorder (MDD) and could become a useful clinical tool.

The blood test, which analyzes levels of nine biomarkers, accurately distinguished patients diagnosed with depression from control participants. There were no significant false-positive results.

Developed by Ridge Diagnostics (Research Triangle Park, NC, USA), the test measures levels of biomarkers associated with factors such as inflammation, the development and maintenance of neurons, and the interaction between brain structures involved with stress response and other key functions.

The measurements are combined using a specific formula to produce a figure called the MDDScore, a number from 1 to 100 indicating the percentage likelihood that the individual has major depression. In clinical use the MDDScore would range from 1 to 10.

The initial study included 36 adults who had been diagnosed with major depression at the Massachusetts General Hospital (MGH; Boston, MA, USA), Vanderbilt University or Cambridge Health Alliance (Cambridge, MA, USA) and 43 control participants from St. Elizabeth's Hospital (Brighton, MA, USA).

MDDScores for 33 of the 36 patients indicated the presence of depression, while only 8 of the 43 controls had a positive test result. The average score for patients was 85, while the average for controls was 33. A second replication phase study included 34 patients from the MGH and Vanderbilt, 31 of whom had a positive MDDScore result. Combining both groups indicated that the test could accurately diagnose major depression with a sensitivity of about 90 % and a specificity of 80 %.

A report of the studies was published in the December 2011 journal Molecular Psychiatry.

"Traditionally, diagnosis of major depression and other mental disorders has been made based on patients' reported symptoms, but the accuracy of that process varies a great deal, often depending on the experience and resources of the clinician conducting the assessment," said George Papakostas, MD, of the MGH department of Psychiatry, lead and corresponding author of the report. "Adding an objective biological test could improve diagnostic accuracy and may also help us track individual patients' response to treatment."

Antidepressant drugs are the most frequently prescribed medication in the United States today where depression strikes over 19 million adults each year–more than coronary artery disease, cancer, or AIDS. Objective biological test information about depression may aid physicians in the differential diagnosis of MDD, the selection of proper treatment, and effective management of their patients.

Related Links:

Ridge Diagnostics
Massachusetts General Hospital
Cambridge Health Alliance



CELLAVISION AB
MEDLAB Asia
KARL HECHT GMBH & CO KG

Channels

Microbiology

view channel
Image: The Xpert MTB/RIF cartridge-based, fully automated molecular diagnostic test for tuberculosis (Photo courtesy of Cepheid).

Test Helps Physicians Remove Suspected TB Patients from Isolation

Tuberculosis (TB) is caused by the Mycobacterium tuberculosis complex (MTB-complex) and usually attacks the lungs and many people carry the MTB-complex bacteria without ever developing active disease.... Read more

Lab Tech.

view channel
Image:  The Flame – a miniature spectrometer for medical diagnostics, biotechnology, and life sciences, that brings flexible optical sensing power to laboratory and point-of-care instrument integration (Photo courtesy of Ocean Optics).

Next Generation Miniature Spectrometer Brings Flexibility to Diagnostics and Biotechnology

The mini spectrometer combines decades of pioneering miniature spectrometer design expertise with leading techniques, adding flexible optical sensing power to laboratory and point-of-care instrument integration.... Read more

Industry News

view channel
Image: Under a new partnership for liquid handling measurement automation, Artel will provide STRATEC’s innovative “Tholos” technology, which measures liquid and solid contents of 96- and 384-well microplates, under the name Artel “SDS” - Sample Detection System (Photo courtesy of Artel).

Artel Expands Portfolio with STRATEC Partnership for Automation Technology

Artel (Westbrook, Maine, USA), a leader in laboratory liquid handling measurement systems, and STRATEC Biomedical AG (Birkenfeld, Germany), a leader in automated systems for clinical diagnostics and biotechnology,... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
08 Mar 2015 - 12 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.